Biomarker targeting pulmonary vaculopathy of pulmonary hypertension and association of them with gene polymorphism

2015 Fiscal Year Final Research Report

• Project/Area Number: 25461148
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Respiratory organ internal medicine
• Research Institution: Chiba University
• Principal Investigator: Tanabe Nobuhiro 千葉大学, 医学(系)研究科(研究院), 特任教授 (40292700)
• Co-Investigator(Kenkyū-buntansha): SAKAO SEIICHIRO 千葉大学, 医学部附属病院, 講師 (80431740)
• Co-Investigator(Renkei-kenkyūsha): SATO TORU 杏林大学, 医学部, 教授 (20170764) ; NAKANISHI NORIHUMI 独立行政法人国立循環器病研究センター, 心臓内科, 部長 (80164234) ; UEDA HATSUE 独立行政法人国立循環器病研究センター, 病理部臨床病理科, 部長 (40522983)
• Project Period (FY): 2013-04-01 – 2016-03-31
• Keywords: 肺高血圧症 / 慢性血栓塞栓性肺高血圧症 / 肺動脈性肺高血圧症 / バイオマーカー / オーダーメード治療 / 右心機能

Outline of Final Research Achievements

The purpose of this study is to elucidate new pulmonary vascular biomarkers ; to find association of them with severity of pulmonary hypertension, surgical outcome in chronic thromboembolic pulmonary hypertension (CTEPH), prognosis; to investigate the association of activity of the biomarkers and gene polymorphism for personalized medicine. Pentlaxin-3 (PTX-3) was the most sensitive biomarker of CTEPH and may be useful marker for early diagnosis, although PTX3 levels did not correlate with the severity of the pulmonary hemodynamics even stratified by gene polymorphisms. Preoperatively high fibrinogen and low plasminogen values in CTEPH are associated with poor long-term postoperative outcome. For PET, accumulation on pulmonary arterial wall was high in some of CTEPH, but the level of SUV max was lower than sarcoma of the pulmonary artery. Finally we found 4 new pulmonary specific peptide biomarkers associated with CTEPH using the protein array method for screening of autoantibodies.

Free Research Field

呼吸器内科学